herbal-medicine-compliance

# Herbal Medicine Compliance Full regulatory workflow for botanical and herbal medicinal products. Sits between pharmaceutical, food supplement, and traditional medicine frameworks — wrong classification adds 3-7 years to launch. ## Decision Flow ```dot digraph { rankdir=TB; node [shape=box style=rounded fontsize=10]; classify [label="1. Classify product:\nmedicine / supplement / cosmetic\n/ TCM / Kampo / food"]; plant [label="2. Per-plant check:\nbanned, restricted, monograph,\nnovel food status"]; framework [label="3. Pick framework:\nTHMPD 2004/24, DSHEA,\nNMPA TCM, BELFRIT, ANSES,\nKampo monograph"]; quality [label="4. Quality control:\nadulteration, heavy metals,\npesticide MRLs, microbial"]; evidence [label="5. Evidence: 30y use\n(15y EU) for THMP, or\nclinical for botanical drug"]; label [label="6. Labeling: no disease claims,\nDSHEA disclaimer, THR mark"]; reg [label="7. Notification / registration\nper market"]; sell [label="8. Place on market"]; classify -> plant -> framework -> quality -> evidence -> label -> reg -> sell; } ``` ## EU -- Traditional Herbal Medicinal Products Directive (THMPD) 2004/24/EC | Aspect | Detail | |--------|--------| | **Legal basis** | Directive 2004/24/EC amending Directive 2001/83/EC on medicinal products for human use | | **Eligibility** | Herbal medicine in use for ≥30 years total, ≥15 years in EU | | **Indications** | Only minor self-limiting conditions (cough, indigestion, joint discomfort, mild anxiety). NO serious disease claims | | **Authority** | National competent authority + EMA HMPC (Committee on Herbal Medicinal Products) | | **Monographs** | HMPC publishes Community Herbal Monographs (CHMs) and EU List entries — once on list, simplified registration | | **Documentation** | Quality dossier (CTD Module 3) + bibliographic evidence of safety + traditional use evidence (30y/15y) | | **GMP** | EU GMP Part II for active substances, Part I for finished products. Inspections required | | **Marking** | Product marked "Traditional herbal medicinal product for use in [indication] exclusively based upon long-standing use" | | **Pharmacovigilance** | Full PSUR + ICSR reporting obligations (same as authorized medicines) | | **Cost** | EUR 50,000-200,000 per dossier; EUR 5,000-25,000 per MS registration fee | | **Timeline** | 12-24 months | ### Key HMPC Monographs in Force (2026) | Botanical | Latin | Indication scope | |-----------|-------|------------------| | **Echinacea purpurea** | Echinaceae purpureae herba | Common cold | | **Valerian** | Valerianae radix | Mild nervous tension, sleep | | **St John's wort** | Hyperici herba | Mild depressive symptoms (well-established use) / mild tension (traditional) | | **Ginkgo** | Ginkgo folium | Vertigo, tinnitus, cognitive symptoms | | **Ginger** | Zingiberis rhizoma | Motion sickness | | **Milk thistle** | Silybi mariani fructus | Liver function support | | **Saw palmetto** | Sabalis serrulatae fructus | BPH urinary symptoms | | **Hawthorn** | Crataegi folium cum flore | Cardiac symptoms | | **Peppermint** | Menthae piperitae aetheroleum | IBS, dyspepsia | ## US -- Two Distinct Paths ### Path 1: Dietary Supplement (DSHEA 1994) | Aspect | Detail | |--------|--------| | **Legal basis** | Dietary Supplement Health and Education Act, codified in 21 USC 321(ff), 343, 350b | | **FDA notification** | NDI (New Dietary Ingredient) notification 75 days before marketing if ingredient marketed AFTER Oct 15, 1994 | | **Old Dietary Ingredients** | Pre-DSHEA ingredients exempt from NDI notification (list maintained informally by industry) | | **Claims** | Structure/function claims allowed ("supports immune function"). Disease claims PROHIBITED. Required disclaimer "This statement has not been evaluated by FDA" | | **GMP** | 21 CFR 111 cGMP for dietary supplements — mandatory since 2010 | | **Adverse event reporting** | Mandatory within 15 days of serious AE (21 USC 379aa-1) | | **Cost** | NDI: USD 30,000-150,000 (toxicology dossier). GMP audit: USD 50,000-200,000 annual | ### Path 2: Botanical Drug (FDA Guidance 2016) | Aspect | Detail | |--------|--------| | **Pathway** | NDA (New Drug Application) under FD&C Act | | **Special guidance** | "Botanical Drug Development Guidance for Industry" — December 2016 | | **Approvals to date** | Only 2 approved: Veregen (sinecatechins, 2006) + Mytesi/Fulyzaq (crofelemer, 2012). Several Phase III in progress | | **Path A (well-known botanical)** | Reduced CMC + non-clinical requirements | | **Cost** | USD 50M-300M including Phase III | | **Timeline** | 7-12 years | ## UK -- MHRA Traditional Herbal Registration (THR) | Aspect | Detail | |--------|--------| | **Legal basis** | Human Medicines Regulations 2012 (SI 1916), Part 7 — UK transposition of THMPD | | **Mark** | THR mark on packaging — required + distinguishable from POM (prescription) + GSL (general sales) | | **Eligibility** | 30 years use total, 15 years in EU + UK (UK still recognizes EU history for pre-Brexit data) | | **Indications** | Only minor self-limiting conditions | | **Fee** | GBP 3,750 application + GBP 50,000-150,000 dossier prep | | **Renewal** | 5-year renewal cycle | | **Brexit divergence** | UK accepting EMA HMPC monographs but assessing independently | ## Germany -- Kommission E + AMG | Aspect | Detail | |--------|--------| | **Kommission E** | Federal Health Office expert panel — published 380 herbal monographs 1978-1994 (still authoritative reference globally) | | **Apothekenpflichtig vs Freiverkäuflich** | Prescription-only / pharmacy-only / freely sellable — German Pharmacy Operations Regulation | | **OTC herbal market** | One of largest globally — EUR 1.5B/year | | **AMG (Arzneimittelgesetz)** | German Medicines Act — interfaces with EU rules. National additional standards | | **BfArM** | Federal Institute for Drugs and Medical Devices — assesses herbal medicine registrations | | **Standard authorization** | Allowed for products fulfilling Kommission E monograph criteria — simpler path | ## France -- ANSES + Plantes Médicinales List | Aspect | Detail | |--------|--------| | **148 medicinal plants** | Annex of Decree 2008-841 — plants authorized for general sale outside pharmacy. Within pharmacy: full Pharmacopoeia | | **Pharmacopée française** | French Pharmacopoeia — plant monographs, quality standards | | **ANSES** | French Agency for Food, Environmental and Occupational Health Safety — supplements | | **Telemed declaration** | Food supplement declaration required before marketing (Décret 2006-352) — ANSES portal | | **Pharmacy monopoly** | Pharmacists hold monopoly on 540+ medicinal plants. Selling outside the 148-list outside pharmacy = practicing pharmacy illegally | | **DGCCRF enforcement** | Regular sweeps of online supplement sellers — annual seizures | ## Italy / Belgium -- BELFRIT List | Aspect | Detail | |--------|--------| | **BELFRIT** | Belgium, France, Italy harmonized list — botanical supplements | | **Status** | 1,028 plants on harmonized list (consolidated 2014, updated 2018) | | **Use** | Each plant categorized: permitted, restricted with conditions, prohibited | | **Scope** | Italy: Decreto 9 luglio 2012 — uses BELFRIT-derived list (1,231 plants) | | **Belgium**: AR 29 août 1997 botanicals list | | **France**: Plantes Plantes 148-list overlaps but is narrower | ## China -- TCM Regulation | Aspect | Detail | |--------|--------| | **NMPA Drug Administration Law (2019 revision)** | TCM (Traditional Chinese Medicine) as registered drug category | | **Chinese Pharmacopoeia (Ph. Chin.)** | 2025 edition — 5,000+ monographs | | **TCM categories**: Class 1 (new TCM) — full clinical. Class 2 (compound preparations from authorized herbs). Class 3 (proprietary TCM with classical formula record) | | **Classical Famous Formula Pathway** (since 2017) | 100+ historical formulas — simplified registration (no Phase III required if classical) | | **Imported TCM** | Foreign TCM products require full NMPA registration. CFDA factory audit | | **Cost** | CNY 5M-50M depending on category | | **Timeline** | 18 months (classical formula) to 6+ years (Class 1 new TCM) | ## Japan -- Kampo | Aspect | Detail | |--------|--------| | **Kampo medicines** | Japanese adaptation of Chinese herbal medicine — ~148 formulas reimbursed by national health insurance | | **Dual classification** | Some Kampo are "ethical drugs" (prescription) reimbursed by NHI. Others are OTC under Pharmaceutical Affairs Law | | **MHLW notification** | Required. Standards based on Japanese Pharmacopoeia (JP XVIII, 2021) + Kampo-specific monographs | | **Marketing Authorization Holder** | Japan-based entity | | **GMP** | Japan-specific GMP for Kampo manufacturers | ## WHO + Quality Standards | Standard | Coverage | |----------|----------| | **WHO Guidelines on Good Agricultural and Collection Practices (GACP)** | 2003 — quality from farm | | **WHO Guidelines on Quality Control Methods for Herbal Materials** | 2011 — testing protocols | | **WHO Monographs on Selected Medicinal Plants** | Volumes 1-4 — 118 plants | | **USP-NF Botanical** | US Pharmacopoeia monographs | | **EP / Ph. Eur. monographs** | European Pharmacopoeia — 270+ plant monographs | | **BP (British Pharmacopoeia)** | UK monographs (largely aligned EP) | ## Contamination Limits ### Heavy Metals (typical, EP Ch 5.20) | Metal | Limit (mg/kg dry weight) | |-------|--------------------------| | Lead (Pb) | ≤5.0 | | Cadmium (Cd) | ≤1.0 (≤0.5 if daily intake >100 g) | | Mercury (Hg) | ≤0.1 | | Arsenic (As) inorganic | ≤5.0 | ### Pesticide Residues -- Reg 396/2005 - Default 0.01 mg/kg for non-authorized pesticides - Plant-specific MRLs in Annex IV - Higher tolerance for dried herbs (concentration factor up to 10x) ### Microbial Limits (EP 5.1.4 / 5.1.8) | Use | TAMC | TYMC | Bile-tolerant Gram-neg | Salmonella | |-----|------|------|-----------------------|------------| | Herbal teas (boiled use) | 10⁷ CFU/g | 10⁵ CFU/g | 10⁴ CFU/g | Absent 25 g | | Herbal medicines (not boiled) | 10⁵ CFU/g | 10⁴ CFU/g | 10³ CFU/g | Absent 25 g | ### Adulteration Testing | Method | Application | |--------|-------------| | **HPLC-UV / DAD** | Marker compound identification (e.g., echinacoside in Echinacea, withanolides in Ashwagandha) | | **HPTLC** | Pharmacopoeial identification — many EP monographs use TLC fingerprint | | **DNA barcoding** | Species authentication (ITS2, matK, rbcL markers). Standard at Health Canada NHP, USP, increasingly EU | | **NMR fingerprinting** | Whole-extract authentication | | **ICP-MS** | Heavy metals quantification | | **GC-MS** | Pesticides + essential oil analysis | ## Per-Plant Regulation Table (high-priority botanicals 2026) | Botanical | EU Status | US Status | UK | Restrictions | |-----------|-----------|-----------|-----|--------------| | **Echinacea purpurea/angustifolia** | HMPC monograph, THMP | DSHEA — old ingredient | THR available | Pollen allergy warning | | **Ginseng (Panax ginseng)** | HMPC monograph | DSHEA — old ingredient | THR available | Anticoagulant interaction warning | | **Saw palmetto (Serenoa repens)** | HMPC monograph, THMP | DSHEA | THR available | Anti-androgen — male users only by precaution | | **Turmeric (Curcuma longa)** | Food + supplement; high-dose >300 mg curcuminoids: hepatotoxicity warning per ANSES + Italian sales suspended 2019, returned 2020 with restriction | DSHEA — black-box warning emerging | Supplement; MHRA monitoring | Bile duct obstruction contraindication | | **Ashwagandha (Withania somnifera)** | Food supplement most MS; Denmark + Sweden + Norway issued risk assessments 2020-2024 warning of thyroid + hepatotoxic risk + 17 case reports; FR limited 2024 | DSHEA | Supplement; MHRA monitoring | Pregnancy contraindication; thyroid + hepatic warning | | **St John's wort (Hypericum perforatum)** | Well-established medicine in DE/AT; THMP elsewhere | OTC supplement; FDA warning on drug interactions | THR + POM (prescription strengths) | Major CYP3A4 inducer — contraceptive failure, immunosuppressant + antiretroviral interactions | | **CBD (Cannabidiol)** | Novel food (since 2019 EFSA decision). UK + EU MS authorizing case-by-case. THC <0.2% (EU) or 0.3% (US) | Hemp-derived legal under 2018 Farm Bill (<0.3% THC). FDA: not approved as supplement — enforcement discretion. Epidiolex (purified CBD) is prescription drug | Novel food authorization required by FSA; >50 products under assessment | Heavy state variation US; Italy banned synthetic CBD 2023 | | **Kratom (Mitragyna speciosa)** | NOT authorized as supplement; controlled in DK/SE/FI/LV/LT/PL/RO/IT (since 2016) | Federal: not scheduled but FDA import alert 54-15; State bans: AL, AR, IN, RI, VT, WI. Regulated supplement: TN, GA, KY, NV (KCPA) | Class B controlled (2024 update under Psychoactive Substances Act 2016) | High abuse + dependence potential | | **Kava (Piper methysticum)** | Lifted EU ban in 2007 after WHO review; still restricted in UK, DE | Banned in some states; FDA consumer advisory | Banned for supplements; allowed traditional cultural use | Hepatotoxicity history |